ClinicalTrials.gg
RecruitingNCT06824103Updated Jun 8, 2026

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

A Phase 4 interventional study of Ruxolitinib in Graft vs. Host Disease, Chronic Graft vs. Host Disease and Corticosteroid-refractory Chronic Graft vs. Host Disease, sponsored by Novartis Pharmaceuticals. Recruiting at 22 sites in China. Open to participants aged 12 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
12 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ruxolitinib in Graft vs Host Disease — 13 open to participants now, 16 under way, 2 of them phase 3. ruxolitinib · Graft vs Host Disease.

Planned enrollment
15th of 27
50 · median 54
Started
2025
with 5 others
Phase 4
3 of 27
1 open now
Primary completion
2029-05
later than 11 of 15 live
Registered
18th of 27
by date
Lead sponsor
6 of 27
Novartis Pharmaceuticals

Among the 27 studies testing ruxolitinib in Graft vs Host Disease, this one is the 15th largest by planned enrollment, is one of 6 that started in 2025, is one of 3 in phase 4, reaches primary completion later than 11 of the 15 other live ones, and was the 18th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

13 of the 27 studies testing ruxolitinib in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 12 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ruxolitinib in Graft vs Host Disease, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).

Read the detailed description

This is a single arm, multi-center, open label study which will enroll approximately 50 participants and investigate the efficacy and safety of ruxolitinib administered in adult and adolescent (≥12 years old) Chinese participants with SR-cGvHD.

The total duration on study for an individual participant will be up to 164 weeks (approximately 3 years).

The study consists of following periods, with each cycle comprised of 4 weeks (28 days):

  • Screening Period (Day -28 to Day -1)
  • Treatment period (Day 1 to Cycle 39/EOT)
  • Safety follow-up (Last dose +30 days)
  • Long-term survival follow-up period (EOT to 156 weeks on study).
03

Conditions studied

  • Graft vs. Host Disease
  • Chronic Graft vs. Host Disease
  • Corticosteroid-refractory Chronic Graft vs. Host Disease

Browse trials for

Keywords

  • cGvHD
  • GvHD
  • SR-cGvHD
  • ruxolitinib
  • INC424
  • Chinese adult
  • Pediatric
  • Corticosteroid
  • refractory
04

Who can participate

Ages eligible
12 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Male or female Chinese participants aged 12 or older at the time of informed consent
  • Able to swallow tablets.- Have undergone alloSCT from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative, myeloablative, and reduced intensity conditioning are eligible.
  • Evident myeloid and engraftment:

    • (ANC) >1,000/mm3 AND
    • Platelet count ≥25,000/mm3

Note: Use of growth factor supplementation and transfusion support is allowed during the trial, however, transfusion to reach a minimum platelet count for inclusion is not allowed during screening and at baseline.

  • Participants with clinically diagnosed cGvHD staging of moderate to severe according to NIH Consensus Criteria (Jagasia et al 2015) prior to Cycle 1 Day 1.

    • Moderate cGvHD: at least one organ (not lung) with a score of 2, 3 or more organs involved with a score of 1 in each organ, or lung score of 1.
    • Severe cGvHD: at least 1 organ with a score of 3, or lung score of 2 or 3.
  • Participants currently receiving systemic for the treatment of cGvHD for a duration of \< 12 months prior to Cycle 1 Day 1, and have a confirmed diagnosis of corticosteroid cGvHD defined per 2014 NIH consensus criteria (Martin et al 2015) irrespective of the concomitant use of a calcineurin inhibitor, as follows:

    • A lack of response or disease progression after administration of minimum prednisone 1 mg/kg/day for at least 1 week (or equivalent) OR
    • Disease persistence without improvement despite continued treatment with prednisone at >0.5 mg/kg/day or 1 mg/kg/every other day for at least 4 weeks (or equivalent) OR
    • Increase to prednisone dose to >0.25 mg/kg/day after two unsuccessful attempts to taper the dose (or equivalent)
  • Participants has (ECOG) performance status of 0-2

Exclusion criteria

Exclusion Criteria:

For a full list of exclusion criteria, refer to Section 5.2. Key exclusion criteria include

  • Participants who have received two or more systemic treatments for cGvHD in addition to ± CNI for cGvHD.
  • Participants who have received ROCK2 inhibitors for cGvHD.
  • Participants that transition from active aGvHD to cGvHD without tapering off corticosteroids ± CNI and any systemic treatment

Note: Participants receiving up to 30 mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids are allowed.

  • Participants who were treated with prior JAK inhibitors for aGvHD; except when the participant achieved complete or partial response and has been off JAK inhibitor treatment for at least 8 weeks prior to Cycle 1 Day 1.
  • Failed prior alloSCT within the past 6 months from Cycle 1 Day 1.
  • Participants with primary , or who have been treated for relapse after the alloSCT was performed.
  • SR-cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for pre-emptive treatment of malignancy recurrence. Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible.

Other protocol-defined inclusion/exclusion may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Ruxolitinib

    Chinese participants (adult and pediatric) who will receive ruxolitinib daily.

    Drug: Ruxolitinib

Interventions

  • Ruxolitinib is taken orally daily at 10 mg BID, given as two 5 mg tablets.

    Also known as: INC424

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response, according to National Institute of Health (NIH) Consensus Criteria.

    Time frame: Cycle 7 Day 1; each Cycle =28 days

Secondary outcomes

  1. Failure-free Survival (FFS)

    FFS is defined as the time from the date of start of study treatment to the earliest of: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) nonrelapse mortality, or iii) addition or initiation of another systemic therapy for cGvHD.

    Time frame: up to 3 years

  2. Best Overall Response (BOR)

    Percentage of participants who achieved overall response (CR+PR) at any time point (up Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD).

    Time frame: at any point up to cycle 7 day 1 (each cycle is 28 days) or the start of additional systemic therapy for cGvHD, approx. 6 months

  3. ORR at end of cycle 3

    Percentage of participants who achieved overall response (CR+PR) at Cycle 4 Day 1.

    Time frame: end of cycle 3; each cycle = 28 days

  4. Duration of Response (DOR)

    DOR is assessed for responders only and is defined as the time from first response until cGvHD progression, death, or the date of addition of systemic therapies for cGvHD.

    Time frame: from first response until cGvHD progression, death, or the date of addition of systemic therapies for cGvHD, approx.36 months

  5. Overall Response (OS)

    OS is defined as the time from the date of study treatment (ruxolitinib) initiation to the date of death due to any cause.

    Time frame: from the date of study treatment (ruxolitinib) initiation to the date of death due to any cause, approx. 36 months

  6. Non-Relapse Mortality (NRM)

    NRM is defined as the time from date of study treatment (ruxolitinib) initiation to date of death not preceded by underlying disease relapse/recurrence.

    Time frame: from date of study treatment (ruxolitinib) initiation to date of death not preceded by underlying disease relapse/recurrence, approx. 36 months

  7. Malignancy Relapse/Recurrence (MR)

    Malignancy relapse/recurrence is defined as the time from date of study treatment to hematologic malignancy relapse/recurrence.

    Time frame: from date of study treatment to hematologic malignancy relapse/recurrence, approx. 36 months

  8. Reduction of daily corticosteroids dose at cycle 7 day 1

    Systemic corticosteroid use is the percentage of participants with \>=50% reduction from baseline in daily corticosteroid dose, the proportion of subjects with reduction from baseline to ≤ 0.2 mg/kg/day methylprednisolone (or equivalent dose of ≤ 0.25 g/kg/day prednisone or prednisolone), and subjects successfully tapered off all systemic corticosteroids at Cycle 7 Day 1, by time intervals and overall.

    Time frame: Cycle 7 Day 1; each cycle = 28 days

07

Study locations

22 of 22 sites recruiting
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
    Recruiting
  • Novartis Investigative Site
    Guangzhou, Guangdong 510000, China
    Recruiting
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
    Recruiting
  • Novartis Investigative Site
    Nanning, Guangxi 530021, China
    Recruiting
  • Novartis Investigative Site
    Guiyang, Guizhou 550004, China
    Recruiting
  • Novartis Investigative Site
    Shijiazhuang, Hebei 050000, China
    Recruiting
  • Novartis Investigative Site
    Zhengzhou, Henan 450003, China
    Recruiting
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
    Recruiting
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
    Recruiting
  • Novartis Investigative Site
    Xuzhou, Jiangsu 221003, China
    Recruiting
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
    Recruiting
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
    Recruiting
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
    Recruiting
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
    Recruiting
  • Novartis Investigative Site
    Ningbo, Zhejiang 315016, China
    Recruiting
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325000, China
    Recruiting
  • Novartis Investigative Site
    Beijing, 100034, China
    Recruiting
  • Novartis Investigative Site
    Beijing, 100070, China
    Recruiting
  • Novartis Investigative Site
    Changsha, 410000, China
    Recruiting
  • Novartis Investigative Site
    Chongqing, 400016, China
    Recruiting
  • Novartis Investigative Site
    Shanghai, 200025, China
    Recruiting
  • Novartis Investigative Site
    Wujiang Nongchang, 065201, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for May 2029, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 13, 2025
StartActual
Sep 9, 2025
Primary completionEst.
May 10, 2029
CompletionEst.
May 23, 2031
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06824103
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Sep 9, 2025
Primary completion
May 10, 2029 (estimated)
Completion
May 23, 2031 (estimated)
Last update
Jun 8, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion